The Evolution of Long-Acting Therapies
The most significant advancement in 2026 is the widespread adoption of Long-Acting Growth Hormone (LAGH). For decades, GHD patients were required to self-administer painful injections every single night.
Modern LAGH formulations use "prodrug" technology or molecular fusion to slow the release of the hormone in the body. This allows for once-weekly injections that provide a steady, sustained level of IGF-1. This shift has dramatically improved "treatment adherence," especially among teenagers. The steady-state delivery of weekly versions more closely mimics natural physiological levels, reducing the "peaks and valleys" of hormone concentration associated with daily shots.
3 Views